Valneva reports nine-month 2024 financial results and provides corporate updates

Nine-month key financial highlights total revenues of €116.6 million, including product sales of €112.5 million net profit of €24.7 million, including proceeds from the priority review voucher (prv)1 sale operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 cash position of €156.3 million includes €61.2 million in gross proceeds from recent private placement2 lower cash burn expected in the second half of 2024 as cost contributions to the agreed r&d budget for partnered lyme disease program were completed in the second quarter of the year full-year 2024 financial guidance narrowed expected total product sales according to guidance between €160 million to €170 million and currently anticipated total revenues between €170 million and €180 million expected r&d investments between €65 million and €75 million expected other income between €100 million and €110 million, including €95 million from the prv sale launch of the world's first chikungunya vaccine in canada and europe underway; further potential approvals expected in brazil (q4 2024) and the uk (q1 2025); strategic pipeline expansion, strong clinical and regulatory execution         secured exclusive worldwide license for s4v2 shigella vaccine candidate, adding an attractive phase 2 clinical asset to valneva's r&d pipeline3 - recently granted fda fast track4 submitted key label extension(s) for ixchiq® in europe and canada5 published ixchiq® two-year antibody persistence and safety data in the lancet infectious diseases6 further demonstrating the vaccine's highly differentiated immunological profile awarded new $41.3 million cepi grant7 to contribute significantly to ixchiq® phase 4 costs and other studies supporting broader access to the vaccine pfizer completed primary vaccination (three doses) in phase 3 valor lyme disease trial8 advancing phase 1 clinical trial for second-generation zika vaccine candidate toward expected data readout and further decision on potential development path in 20259 financial information (unaudited results, consolidated per ifrs) € in million nine months ended september 30,   2024 2023 total revenues 116.6 111.8 product sales 112.5 106.1 net profit/(loss) 24.7 -69.3 adjusted ebitda10 48.6 -46.0 cash 156.3 171.3 saint-herblain (france), november 7, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended september 30, 2024. the condensed consolidated interim financial results are available on the company's website ( financial reports – valneva ).
VALN Ratings Summary
VALN Quant Ranking